Novo Nordisk stock gains 1.12 percent ahead of November 4 results
Published on 10/15/2026 at 10:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBuyback progress and reporting date
- BMO Capital cut its target from USD 47.00 to USD 40.00 on October 12, 2026.
- Novo Nordisk repurchased 23.09 million B shares under its May program by October 9, 2026.
- Novo Nordisk stock trades at EUR 34.41 at 10:40 a.m. CEST at Lang & Schwarz on October 15, 2026, 1.12 percent above the Xetra close of October 14, 2026.
- Novo Nordisk is scheduled to publish its first nine months results on November 4, 2026.
Novo Nordisk stock (ISIN DK0062498333) was trading at EUR 34.41 at Lang & Schwarz on October 15, 2026, 1.12 percent above the Xetra close of October 14, 2026 at EUR 34.03. The euro quote gives investors a firm market reference before the company publishes its first nine months results on November 4, 2026.
On October 12, 2026, BMO Capital lowered its price target from USD 47.00 to USD 40.00 while keeping a Market Perform rating, as Markets Insider reported. The note said Wegovy HD injectable uptake was underappreciated, while growth of the Wegovy pill was already reflected in expectations.
Buybacks add a capital signal
Novo Nordisk reported on October 12, 2026, that it had repurchased 23.09 million B shares under the program running from May 6, 2026, through February 1, 2027. The transactions totaled DKK 6.76 billion, while purchases since February 4 reached 37.85 million shares worth DKK 10.56 billion, according to StockTitan. Treasury shares stood at 1.20 percent of share capital after those transactions.
What does the target cut change?
The chronology is clear: Q2 results on August 4, 2026 showed adjusted sales of DKK 78.49 billion, up 7.00 percent at constant exchange rates, according to via Ritzau; the September 21, 2026 Capital Markets Day set a goal of serving more than 60 million patients by 2030; and the October 12, 2026 buyback update supplied the latest dated company figure. The Q2 adjusted operating profit reached DKK 33.39 billion, up 11.00 percent, but the 2026 adjusted sales and operating profit outlook remained 0% to minus 6% at constant exchange rates.
Dates that shape the next report
Novo Nordisk is scheduled to publish results for the first nine months of 2026 on November 4, 2026, at 7:30 a.m. CEST. The report will test whether volume growth can offset pricing pressure and the lower target levels now set by BMO Capital.
Stock holds above the Xetra close
At EUR 34.41, the Lang & Schwarz quote was 1.12 percent above the EUR 34.03 Xetra close on October 14, 2026. The primary listing is Nasdaq Copenhagen, where Novo Nordisk's B shares trade in Danish kroner.
The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.
Novo Nordisk stock facts
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- WKN: A3EU6F
- Ticker: NOVO-B
- Primary exchange: Nasdaq Copenhagen
- Price Lang & Schwarz (as of October 15, 2026, 10:40 a.m. CEST): EUR 34.41
- Change versus Xetra close: plus 1.12 percent
- Xetra close (October 14, 2026): EUR 34.03
- Market capitalization: EUR 153.2 billion (as of October 15, 2026)
- 52-week range: EUR 30.04-54.87 (as of October 15, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals
- Next earnings date: November 4, 2026
Market context: Latest market reports.
